SkinHealth Systems Inc. (SKIN)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1818093 · fiscal year ends in Dec
Closing price $10.19 on 29 Oct 2026; 52-week range $10.19 to $31.80.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $290.0M
- Revenue growth
- -6.5%
- Net income, last twelve months
- -$28.4M
- Earnings per share
- -$0.22
- Gross margin
- 66.4%
- Operating margin
- -1.5%
- Net margin
- -9.8%
- Free cash flow
- $21.1M
- Return on equity
- -51.2%
- Market value
- $1.3B
- Cash
- $206.1M
- Debt
- $345.2M
- Debt to equity
- 6.21
- Shares outstanding
- 130.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $300.8M | -$20.8M | -$9.5M | -$0.16 | $37.2M | 10-K filed 12 Mar 2026 |
| FY2024 | 31 Dec 2024 | $334.3M | -$67.8M | -$29.1M | -$0.36 | $15.4M | 10-K filed 12 Mar 2025 |
| FY2023 | 31 Dec 2023 | $398.0M | -$130.9M | -$100.1M | -$0.76 | $17.9M | 10-K filed 12 Mar 2024 |
| FY2022 | 31 Dec 2022 | $365.9M | -$25.8M | $44.2M | -$0.23 | -$117.4M | 10-K filed 1 Mar 2023 |
| FY2021 | 31 Dec 2021 | $260.1M | -$39.9M | -$378.8M | -$3.71 | -$39.6M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $72.1M | -$2.7M | -$0.02 |
| Q1 FY2026 | 31 Mar 2026 | $64.9M | -$6.6M | -$0.05 |
| Q4 FY2025 | 31 Dec 2025 | $82.4M | -$8.1M | -$0.06 |
| Q3 FY2025 | 30 Sep 2025 | $70.7M | -$11.0M | -$0.09 |
| Q2 FY2025 | 30 Jun 2025 | $78.2M | $19.7M | $0.03 |
| Q1 FY2025 | 31 Mar 2025 | $69.6M | -$10.1M | -$0.08 |
| Q4 FY2024 | 31 Dec 2024 | $83.5M | -$10.3M | -$0.08 |
| Q3 FY2024 | 30 Sep 2024 | $78.8M | -$18.3M | -$0.15 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Consumables | $212.7M | 70.7% |
| Delivery Systems | $88.1M | 29.3% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Americas | $204.0M | 67.8% |
| Europe, the Middle East and Africa | $68.3M | 22.7% |
| Asia-Pacific | $28.5M | 9.5% |
Company events
The newest 8-K filings of 102 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 14 Oct 2026 | 8-K | Shareholder rights change, Bylaws or fiscal year change, Investor update | 3.03, 5.03, 7.01, 9.01 |
| 6 Oct 2026 | 8-K | Agreement ended, Investor update | 1.02, 7.01 |
| 28 Sep 2026 | 8-K | Shareholder vote | 5.07 |
| 10 Sep 2026 | 8-K | Leadership change | 5.02 |
| 14 Aug 2026 | 8-K | Leadership change | 5.02 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 22 Jun 2026 | 8-K | Other events | 8.01 |
| 16 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 21 May 2026 | 8-K/A | Leadership change | 5.02, 9.01 |
| 12 May 2026 | 8-K | Delisting notice | 3.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 6 May 2026 | 8-K | Leadership change | 5.02 |
Every filing
The newest filings with the SEC of 194 held.
| Filed | Form | Period |
|---|---|---|
| 14 Oct 2026 | 8-K | 14 Oct 2026 |
| 6 Oct 2026 | 8-K | 30 Sep 2026 |
| 28 Sep 2026 | 8-K | 22 Sep 2026 |
| 10 Sep 2026 | 8-K | 3 Sep 2026 |
| 14 Aug 2026 | 8-K | 10 Aug 2026 |
| 12 Aug 2026 | DEFA14A | – |
| 12 Aug 2026 | DEF 14A | 22 Sep 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 31 Jul 2026 | PRE 14A | 22 Sep 2026 |
| 22 Jun 2026 | 8-K | 17 Jun 2026 |
| 16 Jun 2026 | 8-K | 10 Jun 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 20 May 2026 | Menezes Ronald, Former Officer | 165,000 | $114.5K | 20 May 2026 |
| 5 Dec 2025 | BECK MARLA MALCOLM, Former Officer & Director | 5,000 | $8.1K | 5 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Jul 2026 | BlackRock, Inc. | 13G amended | 1% | 1.3M |
| 17 Jul 2026 | BlackRock Portfolio Management LLC | 13G | 5.6% | 7.2M |
| 13 Jul 2026 | Capricorn Fund Managers Ltd | 13G amended | 17.2% | 22.3M |
| 8 Jul 2026 | FMR LLC | 13G amended | 7.9% | 10.2M |
| 11 May 2026 | LCP Edge Holdco, LLC | 13D amended | 25.74% | 33.4M |
| 6 May 2026 | FMR LLC | 13G amended | 13.4% | 17.2M |
| 20 Apr 2026 | Integrated Core Strategies (US) LLC | 13G | 5.1% | 6.5M |
| 6 Feb 2026 | Mirabella Financial Services LLP | 13G amended | 0% | 0 |
| 5 Feb 2026 | Capricorn Fund Managers Ltd | 13G | 15.2% | 19.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 375.7K | -94.82% | 14.26 |
| 30 Sep 2026 | 7.2M | +0.9% | 21.76 |
| 15 Sep 2026 | 7.2M | -0.25% | 24.28 |
| 31 Aug 2026 | 7.2M | +1.84% | 17.44 |
| 14 Aug 2026 | 7.1M | -6.9% | 16.84 |
| 31 Jul 2026 | 7.6M | -13.25% | 9.24 |
| 15 Jul 2026 | 8.8M | -10.16% | 1 |
| 30 Jun 2026 | 9.7M | -21.77% | 4.7 |
Funds that hold it
From each fund's latest Form 13F.
129 funds held it at 30 Jun 2026: 34 added and 42 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Capricorn Fund Managers Ltd | 22,276,935 | $15.4M | +2,872,743 |
| FMR LLC | 10,201,685 | $7.1M | -6,981,546 |
| BlackRock, Inc. | 8,516,203 | $5.9M | +1,158,589 |
| Millennium Management LLC | 7,536,938 | $5.2M | +1,819,478 |
| Vanguard Capital Management LLC | 3,496,485 | $2.4M | +55,477 |
| Woodline Partners LP | 2,328,700 | $1.6M | -3,370,284 |
| Silver Point Capital L.P. | 1,592,030 | $1.1M | 0 |
| D. E. Shaw & Co., Inc. | 1,432,312 | $991.9K | -466,163 |
| Geode Capital Management, LLC | 960,374 | $665.4K | -1,281,222 |
| UBS Group AG | 839,383 | $581.7K | +599,031 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B